The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

It found that people on GLP-1 drugs like Wegovy and Ozempic reported eating fewer processed foods, red meat and sugary drinks ...

A new study has found that people taking Eli Lilly's obesity drug Zepbound lost almost 50% more weight than those using Novo ...

The head-to-head examination of these weight loss drugs provides doctors with 'robust' data on their effectiveness.

Eli Lilly announced that its obesity therapy Zepbound delivered superior outcomes versus Novo Nordisk’s Wegovy across five ...

GLP-1s may help reduce alcohol intake among adults with overweight or obesity, according to data presented at the European ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in ...

While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the ...

Eli Lilly’s (LLY) and Novo Nordisk’s (NVO) weight loss drugs went head-to-head in a weight loss study for the first time — ...

Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group.

Eli Lilly ( NYSE: LLY) on Sunday said that its drug Zepbound (tirzepatide) showed superior weight loss over Novo Nordisk's ( ...